{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"1.5","value":"1.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"description":"TTR is the time from the date of first dosing to the time of the initial response of PR or CR. Response is identified based on CT scans evaluated by IRC per Lugano criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Group D: Open label AZD4205 at 150 mg (RP2D), once daily (Phase 2)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG000","title":"AZD4205 Group D"}],"paramType":"MEDIAN","populationDescription":"Subset of CR or PR responders in Evaluable for CT-based Response Set","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years","title":"Part B: Time to Response (TTR) Assessed by IRC","type":"SECONDARY","unitOfMeasure":"months"}